General Drug Use-results Survey of Rituxan Intravenous infusion - Refractory Pemphigus Vulgaris and Pemphigus Foliaceus -

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031220115

Enrollment

125

Registered

2022-06-04

Start date

2022-06-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pemphigus vulgaris and pemphigus foliaceus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with refractory pemphigus vulgaris and pemphigus foliaceus who have received Rituxan intravenous infusion.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Incidence of adverse events and adverse drug reactions. PDAI activity score, Clinical global impression-improvement, patient global impression-improvement.	—

Contacts

Public ContactJunko Sakamoto

Zenyaku Kogyo, Co., LTD.

Junko_Sakamoto@mail.zenyaku.co.jp+81-3-3946-1136

Outcome results